Special Treat Tianbang turned losses into profits. Director Zhang Banghui admitted: 2024 will be a year of ups and downs | Interpretations
① In 2024, ST Tianbang achieved a Net income of 1.459 billion yuan attributable to the Shareholders of the listed company, a year-on-year increase of 150.58%, marking a turnaround from losses to profits; ② Chairman Zhang Banghui expressed to investors in the annual report that 2024 is a year of ups and downs; ③ ST Tianbang's financial pressure has eased somewhat, but the crisis still exists.
The Social Security Fund's annual report on Hold Positions has been revealed! A total of 52 new stocks entered the top ten circulating Shareholders list, with China Resources Double-Crane Pharmaceutical receiving the most Shareholding increases.
① With the continuous disclosure of the 2024 annual reports of listed companies, the Social Security Fund has newly entered the top ten circulating shareholders list of 52 individual stocks; ② Among them, China Resources Double-Crane Pharmaceutical has the highest number of new holdings by the Social Security Fund, reaching 3; ③ Attached is the list of A-shares where the number of newly added Institutions held by the Social Security Fund in the fourth quarter of 2024 ranks highest (attached table).
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Sunshine Guojian Pharmaceutical (688336): The 2024 Earnings Reports show a revenue growth of 17.70% and a significant increase in Net income of 139.15%.
Sunshine Guojian Pharmaceutical 2024 Earnings Reports: Summary of significant performance growth driven by innovation and future challenges: Financial performance: In 2024, revenue is 1...
Last year's loss narrowed mainly due to cutting R&D? Staidson's performance remains under pressure | Interpretations
① In 2024, Staidson's total revenue has declined again, and the loss continues, with the company having incurred losses for five consecutive years so far. ② During the reporting period, the company's R&D investment was 0.162 billion yuan, a decrease of 63.77% compared to the same period last year, with most major R&D projects in early clinical trial stages.
The market continues to shrink and adjust, raising concerns about a retreat in the Siasun Robot&Automation Sector. Can the deep-sea Technology Concept hold the flag and launch a counterattack?
Track the entire lifecycle of the main Sector.